Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Open access

Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression

M. D. De Ioris F. del Bufalo C. Quintarelli V. Bertaina F. Fabozzi M. Cefalo I. Alessi Chiara Grimaldi M. F. Villani M. L. D'Andrea A. Stracuzzi C. Altini C. Malaspina M. Sinibaldi S. Di Cecca L. Iaffaldano C. Geraci M. Becilli B. De Angelis A. Crocoli G. Cassanelli Stefano Margaritora A. Mastronuzzi F. Locatelli
Sep 2026 · Translational Oncology · Vol 73, pp. 103013 · 0 citations · 39 references
Medicine

TL;DR

Bone/bone marrow metastasis seems to be more sensible to this treatment compared to soft tissue lesions and the percentage of GD2-positive tumor cells tends to decrease under chemoimmunotherapy pressure.

Abstract

Highlights • Chemoimmunotherapy in refractory/relapsed neuroblastoma is well tolerated.• Bone/bone marrow metastasis seems to be more sensible to this treatment compared to soft tissue lesions.• Primary and soft tissue lesions often decrease in metabolic activity despite the absence of radiological response.• The percentage of GD2-positive tumor cells tends to decrease under chemoimmunotherapy pressure.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Case report Open access Oct 2026

[Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.]

The clinical case described concerns a 56-years old woman with triple-negative breast cancer metastic to bone progressed with previous chemotherapy and immunotherapy. Our patient, treated in second line with sacituzumab govitecan, obtained prolonged disease control without severe toxicity e with good quality of life.

Caterina Battaglia · 0 citations
Open access Oct 2026

Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

Diffuse large B ‐ cell lymphoma (DLBCL) remains a clinically and molecularly heterogeneous disease, 1 with approximately one ‐ third of patients developing relapsed or refractory (R/R) disease following frontline immunochemotherapy. 2,3 Among molecularly defined sub-groups, CD79B mutations occur in 5% – 25% of DLBCL

Li Wang, K. Zhou, Fei Li et al. · 0 citations
Sep 2026

ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T‐Cell Lymphoblastic Leukemia/Lymphoma

Relapsed and refractory (R/R) T‐cell acute lymphoblastic leukemia/lymphoma (T‐ALL/T‐LL) remains a therapeutic challenge. Allogeneic hematopoietic stem cell transplantation (HSCT) after achieving complete remission (CR) offers the only chance of cure, but effective modalities to achieve CR are limited. Activation of mTO...

Himalee S. Sabnis, M. Pauly, E. Schafer et al. · 0 citations
Open access Sep 2026

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).

H. Mian, M. Faisal, Tie-Ning Chen et al. · 0 citations
Open access Oct 2026

Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience

Survivors of childhood rhabdomyosarcoma (RMS) are at increased risk of second malignant neoplasms (SMNs), influenced by treatment type and genetic predisposition. Recently, the addition of maintenance chemotherapy with low‐dose cyclophosphamide and vinorelbine has improved survival outcomes for patients with high‐risk...

G. Bisogno, A. Ferrari, Raquel Dávila Fajardo et al. · 0 citations
Open access Oct 2026

Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis

Perioperative treatment with enfortumab vedotin (EV) plus pembrolizumab has demonstrated a high pathological complete response (pCR) rate in patients with cisplatin‐ineligible muscle‐invasive bladder cancer (MIBC). However, whether this therapeutic benefit reflects true pharmacologic synergy or can be explained by inde...

Riko Ikeda, Soichiro Yoshida, Wei Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.